The massive ~51% dilution at a ~1.4% discount to the prior close ($2.90 vs $2.94) signals urgent capital needs despite the recent $117M cash balance. The company's auditor included a going concern qualification in the FY2025 10-K, and this offering only extends runway to mid-2027. Watch for potential further dilution as the company will likely need additional capital before reaching profitability. The 60-day lock-up expiration in early July 2026 could create additional selling pressure.
Price Chart
Executive Summary
Cabaletta Bio is selling 51,725,000 shares of common stock at $2.90 per share in a dilutive follow-on offering, raising approximately $141 million in net proceeds. The offering represents a ~51% increase in shares outstanding (from ~100.5M to ~152.2M), creating immediate dilution of $1.30 per share for new investors. Proceeds will fund expanded clinical development of its lead CAR-T candidate rese-cel and manufacturing scale-up, extending cash runway into mid-2027.
Key Facts
- Offering of 51,725,000 shares at $2.90 per share, raising $150M gross / ~$141M net proceeds
- Shares outstanding will increase from ~100.5M to ~152.2M, a ~51% dilution
- Immediate dilution of $1.30 per share for new investors (offering price $2.90 vs. as-adjusted book value $1.60)
- Preliminary cash balance of ~$117M as of March 31, 2026; pro-forma cash ~$252.6M after offering
- Cash runway extended into mid-2027; prior guidance had cash lasting into first half of 2026
- Underwriters include TD Cowen, Guggenheim Securities, Cantor, and H.C. Wainwright
- 60-day lock-up for insiders and company from pricing date (May 4, 2026)
Financial Impact
~$141M net proceeds raised; ~51% dilution to existing shareholders; immediate per-share dilution of $1.30
Risk Factors
- Massive dilution (~51%) will pressure stock price as new shares hit the market
- Going concern qualification from auditor indicates financial distress risk
- Pre-revenue biotech with no approved products; clinical trial failures could destroy remaining value
- Cash runway only extended to mid-2027; additional capital likely needed before profitability
- Lock-up expiration in ~60 days could lead to insider selling overhang
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-202441 |
| Document: 0001193125-26-202441-index-headers.html | 0001193125-26-202441 |
| Document: 0001193125-26-202441-index.html | 0001193125-26-202441 |
| Document: 0001193125-26-202441.txt | 0001193125-26-202441 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $2.91 $2.46 | ▼ −15.46% | ▼ −15.57% | $1.91 (−34.36%) |
Aug 15, 2026 6w ago | Institutional Cluster | $2.89 $3.10 | ▲ +7.27% | ▲ +8.46% | $1.91 (−33.91%) |
Aug 13, 2026 7w ago | 8-K | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Aug 13, 2026 7w ago | Press Release | $2.71 $3.19 | ▲ +17.71% | ▲ +19.68% | $1.91 (−29.52%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.01 $2.84 | ▼ −5.65% | ▼ −6.32% | $1.91 (−36.54%) |
Jun 3, 2026 17w ago | 8-K | $3.58 $3.04 | ▼ −15.08% | ▼ −11.26% | $1.91 (−46.65%) |
Jun 1, 2026 17w ago | DEFA14A | $3.67 $3.25 | ▼ −11.44% | ▼ −8.69% | $1.91 (−47.96%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▼ −2.22% | ▼ −2.93% | $1.91 (+47.09%) |
May 14, 2026 20w ago | Press Release | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
May 14, 2026 20w ago | 8-K | $3.61 $3.69 | ▲ +2.22% | ▲ +2.93% | $1.91 (−47.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access